| Title |
Valuing Benefits to Inform a Clinical Trial in Pharmacy
|
|---|---|
| Published in |
PharmacoEconomics, December 2012
|
| DOI | 10.1007/s40273-012-0012-7 |
| Pubmed ID | |
| Authors |
Michela Tinelli, Mandy Ryan, Christine Bond, Anthony Scott |
| Abstract |
The generic health-related quality-of-life (HR-QOL) utility measures the EQ-5D and SF-6D are both commonly used to inform healthcare policy developments. However, their application to pharmacy practice is limited and the optimal method to inform policy developments is unknown. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 5 | 7% |
| United States | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 67 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 20% |
| Student > Master | 13 | 18% |
| Student > Ph. D. Student | 11 | 15% |
| Student > Doctoral Student | 8 | 11% |
| Other | 4 | 5% |
| Other | 5 | 7% |
| Unknown | 18 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 24% |
| Nursing and Health Professions | 6 | 8% |
| Economics, Econometrics and Finance | 6 | 8% |
| Social Sciences | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Other | 13 | 18% |
| Unknown | 21 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2013.
All research outputs
#18,327,422
of 22,694,633 outputs
Outputs from PharmacoEconomics
#1,596
of 1,813 outputs
Outputs of similar age
#216,635
of 279,025 outputs
Outputs of similar age from PharmacoEconomics
#68
of 74 outputs
Altmetric has tracked 22,694,633 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,813 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 3rd percentile – i.e., 3% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,025 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 74 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.